The research of Dr. Duda’s group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1) local tumor progression (in liver cancers) and metastatic tumor progression (in other gastrointestinal cancers and in prostate and breast malignancies), and 2) treatment resistance in these cancers. The ultimate goal is to identify and validate targets for combination therapy (with radiation and immunotherapy) in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies. His research is currently supported by grants from the US National Cancer Institute, by The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, Massachusetts General Hospital (MGH) ECOR, and by partnerships with the Industry (Bayer, Bristol Myers Squibb, Exelixis, and Leap Tx).
He has authored nearly 200 publications so far, of which over 110 are original reports, including articles in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, Cancer Discovery, Science Translational Medicine, PNAS, JNCI, and Journal of Clinical Oncology. He has been invited to present his results at over 150 local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures. For his work, Dr. Duda received several awards, including from the American Association for Cancer Research, Cancer Research Institute, International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), MGH and the Granara-Skerry Trust for Pancreatic Cancer Research. He is a Honorary Member of the Academy of Medical Sciences of Romania since 2012.
Dr. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned a PhD in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, he pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH and Harvard Medical School in Boston. He became a Junior Faculty member (Instructor) in 2004, and then rose through the ranks to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School in 2012. In 2016, he was appointed as the Director of Translational Research in Gastrointestinal Radiation Oncology at MGH. He has been active internationally, and is currently serving as the Secretary General of the IASGO since 2015. He has also been serving as a panel member for multiple scientific expert/grant review meetings worldwide since 2009, including as a permanent member of the US NCI DMP, ACS TBG, and Belgium FWO Med4 sections.
(See full CV at: steele.mgh.harvard.edu/data/research_statements/2/Duda_HMS_CV.pdf)